Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 177

Similar articles for PubMed (Select 10964871)

1.

Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study.

Henry ME, Moore CM, Kaufman MJ, Michelson D, Schmidt ME, Stoddard E, Vuckevic AJ, Berreira PJ, Cohen BM, Renshaw PF.

Am J Psychiatry. 2000 Sep;157(9):1506-8.

PMID:
10964871
2.

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.

Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB.

Biol Psychiatry. 1998 Jul 15;44(2):77-87.

PMID:
9646889
3.
4.

Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.

Judge R, Parry MG, Quail D, Jacobson JG.

Int Clin Psychopharmacol. 2002 Sep;17(5):217-25.

PMID:
12177584
5.

Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.

Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC.

J Clin Psychiatry. 2000 Nov;61(11):863-7.

PMID:
11105740
6.
7.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
8.

Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment.

Henry ME, Kaufman MJ, Hennen J, Michelson D, Schmidt ME, Stoddard E, Vukovic AJ, Barreira PJ, Cohen BM, Renshaw PF.

Biol Psychiatry. 2003 Jan 1;53(1):100-5.

PMID:
12513950
9.

Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.

Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dubé EM.

J Clin Psychiatry. 2002 Jul;63(7):577-84.

PMID:
12143913
10.

Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study.

Kaufman MJ, Henry ME, Frederick Bd, Hennen J, Villafuerte RA, Stoddard EP, Schmidt ME, Cohen BM, Renshaw PF.

Biol Psychiatry. 2003 Sep 1;54(5):534-9.

PMID:
12946882
11.
12.
13.

Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration.

Renshaw PF, Guimaraes AR, Fava M, Rosenbaum JF, Pearlman JD, Flood JG, Puopolo PR, Clancy K, Gonzalez RG.

Am J Psychiatry. 1992 Nov;149(11):1592-4.

PMID:
1415832
14.
15.
16.

Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.

Shelton C, Entsuah R, Padmanabhan SK, Vinall PE.

Int Clin Psychopharmacol. 2005 Jul;20(4):233-8.

PMID:
15933485
17.

Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.

Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J.

Clin Ther. 2004 Sep;26(9):1446-55.

PMID:
15531007
19.

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ.

Eur Psychiatry. 2006 Sep;21(6):367-78. Epub 2006 May 11.

PMID:
16697153
20.

Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.

Polsky D, Onesirosan P, Bauer MS, Glick HA.

J Clin Psychiatry. 2002 Feb;63(2):156-64.

PMID:
11874218
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk